Drug-pricing litigation alongside major SEC filings and debt raise

AbbVie is simultaneously navigating legal and financial inflection points, including U.S. DOJ support in its lawsuit challenging Colorado’s drug discount law, signaling heightened federal–state tension over drug pricing regulation. The company has filed its 2025 10-K, providing a full-year snapshot of performance and risk disclosures. In parallel, AbbVie is tapping the bond markets with a seven-part notes offering of up to $8 billion, likely to support balance sheet needs and strategic initiatives. Together, these moves show AbbVie managing regulatory risk while securing long-term capital in a shifting policy environment.